Gardasil Advisory Cmte. Has Advice On Marketing, Not Just PostMarket Trials
Executive Summary
Merck remains on track towards adding the genital warts indication for its Gardasil human papillomavirus vaccine for use by males 9-26 years old following favorable votes on efficacy (7-0, with 1 abstention) and safety (7-1) at FDA's Vaccines & Related Biological Products Advisory Committee on September 9
You may also be interested in...
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.